AlphaTON Capital (ATON) Q1 2025 earnings summary

Executive summary

• Net loss for the quarter ended June 30, 2024 was $1.7 million, a significant improvement from $4.2 million in the same quarter last year.

• Operating expenses decreased to $2.8 million from $5.0 million year-over-year, driven by lower R&D costs.

• Strategic alternatives under exploration include asset partnerships, sale, merger, restructuring, wind down, or further financing.

• Clinical activity reduced as iNKT program discontinued and adenosine trial enrollment paused.

Financial highlights

• R&D expenses dropped 64% year-over-year to $1.3 million due to reduced clinical and manufacturing activity.

• G&A expenses rose slightly to $1.5 million, mainly from higher legal and payroll costs related to retention agreements.

• $1.1 million non-cash gain from warrant liability fair value change in the quarter; prior year included $1.1 million non-cash loss from deferred purchase price and milestone obligations.

• Cash and cash equivalents stood at $3.3 million as of June 30, 2024, with current liabilities of $3.0 million.

• Basic and diluted loss per share was $1.58, compared to $6.69 in the prior year quarter.

Outlook and guidance

• Strategic review ongoing, with options including partnerships, sale, merger, restructuring, wind down, or new financing.

• Plans to replace a withdrawn patient in the ADPORT-601 trial and continue collaborations to advance product candidate understanding.